We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 5.90 | 10.15% | 64.00 | 1,628,046 | 12:02:51 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 63.00 | 65.00 | 64.00 | 57.00 | 57.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -9.14 | 208.6M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:28:37 | O | 8,000 | 63.177 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/10/2024 | 07:00 | UK RNS | Avacta Group PLC Avacta Unveils Pipeline Expansion at EORTC 2024 |
| 10/10/2024 | 07:00 | UKREG | Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted.. |
| 30/9/2024 | 13:14 | ALNC |  EARNINGS: Brighton Pier gives downbeat outlook; Seeen "has momentum" |
| 30/9/2024 | 07:00 | UK RNS | Avacta Group PLC Interim Results |
| 16/9/2024 | 07:00 | UK RNS | Avacta Group PLC Avacta Reported Updated Phase 1 Data of AVA6000 |
| 14/9/2024 | 08:00 | UKREG | Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European.. |
| 12/9/2024 | 07:00 | UK RNS | Avacta Group PLC Notice of Results |
| 09/9/2024 | 07:00 | UK RNS | Avacta Group PLC Avacta to present clinical data at ESMO Congress |
| 08/9/2024 | 23:05 | UKREG | Avacta to present updated clinical data on AVA6000 at the European Society.. |
| 02/9/2024 | 15:53 | UK RNS | Avacta Group PLC Director/PDMR Shareholdings and TVR |
Avacta (AVCT) Share Charts1 Year Avacta Chart |
|
1 Month Avacta Chart |
Intraday Avacta Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/10/2024 | 12:01 | Avacta – Innovative and Disruptive Technologies for Global Health Markets | 58,562 |
| 25/6/2024 | 12:57 | Covid-19. Ten Minute Test. Gamechanger!! | 19,644 |
| 23/4/2024 | 13:44 | avct The Fall!!! | 141 |
| 23/4/2023 | 22:31 | Avacta – Unique and innovative technology blipping on big pharma’s radar | 1,851 |
| 23/2/2022 | 07:14 | CV And The Deep State | 228 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:28:38 | 63.18 | 8,000 | 5,054.16 | O |
| 11:26:20 | 63.83 | 10,933 | 6,978.53 | O |
| 11:21:30 | 63.13 | 799 | 504.37 | O |
| 11:19:52 | 63.13 | 1,000 | 631.26 | O |
| 11:19:43 | 63.82 | 1,090 | 695.62 | O |
| Top Posts |
|---|
Posted at 08/10/2024 09:21 by pwhite73 DB are naughty boys like every other bank that's why they get fined by the FCA and other international financial regulators. However this does not cast dispersions on or discredit their pharmaceutical analysts.40p was the value they put on Avacta and in the 40s is where the share price is. However that is not the serious issue. The serious issue is the company has shown no measurable efficacy for AVA6000. It is this fact that will cost you your entire investment in AVCT if you are still invested and hang around long enough. |
Posted at 03/10/2024 18:34 by mirabeau Avacta Group – Exploring NASDAQ Dual-Listing And Divesting Its Diagnostics Division, Analyst Has 188p Valuation, Shares Now 45.5pMark Watson-Mitchell 03/10/2024 On Wednesday 30th October, Avacta Group (LON:AVCT), the cancer treatments and diagnostics life sciences business, will be presenting a live Research & Development Spotlight entitled Next Generation of pre|CISION Medicines. It is expected that there will be keen investor interest to hear what the group has to say about its pre|CISION platform. The Business Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. It has two main segments: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals. Avacta Therapeutics: which is the clinical stage oncology biotech division that is harnessing the proprietary pre|CISION platform technology to develop novel, highly targeted cancer drugs. The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. Avacta Diagnostics: which focuses on supporting healthcare professionals and broadening access to diagnostics, has two business units – Launch Diagnostics and Coris Bioconcept. Launch Diagnostics is a well-established sales channels in the professional, centralised hospital laboratory testing market in the UK and France. Coris, based in Gembloux, Belgium, develops, manufactures and markets rapid diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals. In the highly competitive diagnostics market, Avacta’s proprietary Affimer® platf This Week’s Interim Results Last Monday morning the group reported its Interim Results for the six months to end-June, showing much in line with expectations, with revenues off slightly at £11.3m (£11.9m) and running at a first-half loss of £12.5m (£11.5m). The Diagnostics division revenues advanced to £11.2m (£9.9m), however, it must be noted that the company has started the process to divest this side of the business, in order to maximise value for shareholders, while ensuring its focus as a therapeutics-focused company and support its appeal to specialist international investors. After the £31.1m cash raise in March this year, the group ended the period with £32.5m cash and cash equivalents, against £26.6m at the same time last year. The first six months of the year saw a number of managerial and operational changes, while its financial position remains in line with the Board’s expectations. Management Comments New Chairman Shaun Chilton stated that: “Over the four months since Chris Alongside the Board and wider team, we have carried&# We are very encouraged by the potential of the innovative medicines in the Avacta pipeline which we plan to present at our live R&D Spotlight in October focusing on the Next Generation of the pre|CISION We have commenced a process to divest the Diagnostics Division and have started to receive indicative offers. Our longer-term financing strategy is being formulated and includes a potential dual listing of the Company on NASDAQ, which the Board sees as a key strategic option for the Company.” Avacta aims to leverage its proprietary pre|CISION™ platform to develop innovative oncology therapies that make a significant difference to cancer patients’ treatment experience and outcomes. The pre|CISION™ platform has the potential to enable patients to achieve improved outcomes with fewer side effects by leveraging the tumor specific enzyme Fibroblast Activation Protein (FAP) to protect normal tissues from toxic drugs. The group is poised to move into the next stage of development, implementing these findings of this drug release mechanism across our innovative pipeline. New CEO Christina Coughlin, MD, PhD, stated that: “We are seeing notably positive progress on our drug development candidate AVA6000 with the completion of the Phase 1a trial with no maximum tolerated dose and opening of the RDE expansion. This novel peptide drug conjugate cont The AVA6000 data in the clinic has led to a growing confidence in the pre|CISION™pla Our next generation programs will leverage the pre|CISION™ platform as a foundation for other tumor-specific warhead delivery systems. This platform will underpin our wider clinical strategy and our ambition of bringing these novel cancer medicines closer to patients and delivering value for shareholders.” Analyst Views At Trinity Delta, its analysts Lala Gregorek and Philippa Gardner consider that Avacta is transitioning into a developer of innovative highly targeted specialist oncology products. They state that once the Diagnostics division has been divested, Avacta will become a fully focused biotech company. That is an important element of the strategy to broaden Avacta’s appeal to specialist healthcare investors via a potential additional listing on NASDAQ, securing sustainable funding for further pipeline development. Trinity Delta concludes by noting that “pending the October R&D event in London we maintain our Avacta valuation of £675m, equivalent to 188p/share.” In My View There is a lot going on within this £161m capitalised group. The recent corporate shake-up appears to have been initially beneficial, and if the divestment goes ahead, and a NASDAQ quote is achieved, this group could well be significantly improving its 45.5p share price within months. Latest News Subscribe to the UK Investor Magazine email newsletter |
Posted at 12/9/2024 19:09 by waldron THE AVCT SHARE PRICEAnd when they were up they were up, And when they were down they were down, And when they were only half way up They were neither up nor down. RESULTS SHOULD SOON CLARIFY share price DIRECTION GOOD LUCK ALL |
Posted at 15/7/2024 09:25 by jaknife Rajraj b,”Should be an interesting week for the share price. We are due some news updates. Let’s see what happens” The only scheduled news update is the quarterly conversion that’s due under the death spiral. In order to maximise their profits from the conversion the market maker that is ultimately the owner of the death spiral needs to: A. Sell shares in the market at the highest price possible, eg by moving the price up (giving the illusion of momentum), which encourages punters to pile in and buy (from the market maker who goes short). B. Buy shares at the lowest price possible, eg by crashing the share price in the run up to the conversion date thus making the VWAP formula for the death spiral produce a low price. Who thinks that the market maker will try to maximise their profit? And hands up who thinks that the market maker is a friendly kind soul who exists to help you make a profit? JakNife |
Posted at 04/7/2024 11:51 by pwhite73 Jaknife - "The rise in the share price simply reflects the market maker moving the share price up."Perhaps but the momentum cannot take place in a vacuum. The company is clearly working hard with some success to reinvent itself but the fundamentals have not changed. That they have a peptide that can target tumours in greater amounts than standard DOX and leave healthy tissue alone is a hoax. |
Posted at 04/7/2024 11:35 by jaknife PWhite73,"The rise in the share price reflects a more credible management team and a more effective PR campaign." The rise in the share price simply reflects the market maker moving the share price up. People assume that buying activity has moved the share price up but that's not necessarily how markets work. The easiest way to encourage buying activity is to create the illusion of momentum first! There's a conversion due on the death spiral in just over two weeks time and hence the market maker needs to sell something like 5m shares between now and then. JakNife |
Posted at 03/6/2024 10:25 by pwhite73 Rajraj b - Yes I still do. AVCT has just raised £28 million. It is my opinion they are not going to waste anymore money on the never ending AVA6000 Phase 1 trials. AVCT needs to boost the share price or they can't meet their loan obligations without totally destroying what's left of shareholder value.AVCT and SOFIE are both looking at the use of FAP to kill cancer cells. AVCT as a means of recognition and SOFIE as a means of inhibition. RNS 28/03/24 - "This sub-study represents an ongoing collaboration between Avacta and SOFIE, in the use of [18F]FAPI-74 PET as a complementary diagnostic. [18F]FAPI-74 PET is currently in clinical development and for investigational use only." So we know they have been working together prior to the date of the RNS. A full joint venture to kill cancer cells will perhaps give AVCT the boost they so desperately need. |
Posted at 29/5/2024 16:10 by bones698 White utter nonsense as usual over 90% of small caps stocks will lose investors money that's why it's a complete gamble and with bad odds. Everyone thinks they have got one of the 10% that comes good but the relaity is they haven't and will lose money.More importantly is when you buy and sell any of them and getting that timing right is crucial to being able to make money in small cap companies. Loom at any number that have raised money recently at huge discounts on already depressed share prices. Most investors are down over 90% on them as you well know. That said if your buying them now you stand a good chance to make money provided they can show some good news in the coming months. The ones that tend to lose are those investing for the long term at the wrong time in the cycle, paying to high a price for hopes and dreams that are years away and need cash to get there. Avacta is such a case imo and we have already seen the share price fall massively because of this Imo there is more of the same to come and with its 120m mkt cap it looks almost certain to fall further as more cash will be required and they are so far away from any revenues or break even from the drugs in trials. I don't hold a lot of shares I post on but I am entitled to my opinion and it's usually in stark contrast to many ramping those shares. The fact I don't hold doesn't stop me having an opinion and commenting on them as those that hold them usually are biased and fail to see the downside. Again just look back here and at mnay other companies. With that in mind and the success rate being so low it's usually the negative posters which are correct and should be listened to a lot more, sadly though how many actually do or end up losing money because they don't shows how silly some investors are when the facts back this up |
Posted at 27/4/2024 15:22 by pwhite73 Down here nobody cares about conviboys, MM games, longs or shorts. This is why the thread is so quiet despite an 8% rise yesterday.What investors want to see is evidence the drug actually works. People who don't know or think they know what's going on blame the falling share price on the death spiral. I've said it before and I'll say it again AVCT does not have death spiral financing and even if it did it is not the reason why the share price has dropped from 180p in February last year to 48p today. The problem for AVCT is that the commercial pharmacology industry has seen no evidence to date that suggests AVA6000 is an improvement on Dox on its own. The data presented so far is not independent and there is no peer review in any medical journals to confirm even partial efficacy of AVA6000. As result of this AVCT cannot source the $billions of dollars normally available for early stage cancer drugs that show promising potential. This is why it had to tap the AIM mug punter market at 50p and not 500p. I have opined countless times before and will say so again AVA6000 is as bogus as the world beating LFT and it does please me that many of my earlier and later critics are beginning to see that I was right all along. |
Posted at 29/2/2024 15:21 by pwhite73 Aman - "A reminder - convis kill companies."Wrong again. AVCT do not have a death spiral in place. The CLN was announced in October 2022 when the share price was at 119p. The share price peaked to 186p in February 2023. It dropped to 95p in July 2023 and rose to 150p in October 2023. There is no correlation between the conversions and the share price. What has gone wrong here is that the share price has failed to respond to the progress the company claims AVA6000 is making. The reasons I have given a million times. It is a mistake to blame the CLN for the decline in the share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
